ArticleJournal of contemporary brachytherapy2025
Personalized brachytherapy in gynecological cancers: procedural narrative in patients with a poor response or challenging anatomy after chemoradiation.
Article in Journal of contemporary brachytherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovative and Customized 3-Dimensional-Printed Mold Brachytherapy Treatment of Genital Extramammary Paget's Disease.Advances in radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Brachytherapy plays a critical role in managing gynecological cancers. However, for patients who have a poor response to chemoradiation or present with complex anatomy, delivering tumoricidal doses may be challenging. In this case series, we present a descriptive narrative of techniques adopted for brachytherapy, dosimetric and early clinical outcomes for such clinical challenging cases. Material and methods: Patients who had a poor response to chemoradiation or with challenging anatomy received individualized brachytherapy between 2021 and 2023. All underwent pre-brachytherapy clinical assessment and MRI. These patients were treated with personalized brachytherapy techniques based on tumor extent and anatomy. Manual dose optimization and adjustments to dose fractionation were tailored on a case-by-case basis maximizing tumor control and limiting organ-at-risk doses. Results: In the six patients included in this report, the median high-risk clinical target volume (HR-CTV) volume was 51.1 cc. For each patient, the implant was individualized using a combination of applicators, 3D-printed applicators or freehand needles. At a median follow-up of 31 months, three out of six patients were locally controlled. Out of the three patients with locally controlled disease, one patient developed grade 2 posterior fourchette necrosis. Conclusions: Though the results provide a descriptive narrative, they also highlight a clinical care gap that brachytherapy alone cannot yet address for patients. Advancing individualized brachytherapy by incorporating novel agents and techniques may help improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.